Molluscum Contagiosum And Verruca Vulgaris Therapeutics
1. Ycanth patent expiration
Treatment: Topical treatment of molluscum contagiosum in adult and pediatric patients 2 years of age and older; Topical treatment of skin lesions caused by an infection with molluscum contagiosum in adult and pe...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12233042 | VERRICA PHARMS | Treatment of cutaneous disorders |
Aug, 2038
(12 years from now) | |
| US11147790 | VERRICA PHARMS | Treatment of cutaneous disorders |
Aug, 2038
(12 years from now) | |
| US11052064 | VERRICA PHARMS | Compositions, methods and systems for the treatment of cutaneous disorders |
May, 2035
(9 years from now) | |
| US12290651 | VERRICA PHARMS | Devices and methods for the treatment of body surface disorders |
Feb, 2041
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 21, 2028 |
Drugs and Companies using CANTHARIDIN ingredient
NCE-1 date: 22 July, 2027
Market Authorisation Date: 21 July, 2023
Dosage: SOLUTION
More Information on Dosage
YCANTH family patents
